Lu AF28996 for Parkinson's Disease Motor Fluctuations
Part of Brain & nervous system clinical trials.
This trial tests a new medication called Lu AF28996 to help reduce the periods when Parkinson's symptoms worsen throughout the day (called 'OFF times'). If you have motor fluctuations that are predictable and affecting your daily life, this study might help you experience fewer of these difficult periods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Parkinson's disease at least 3 years ago, after age 30
- Experience noticeable, predictable motor fluctuations (OFF times) every day that significantly affect your activities
- Motor fluctuations have been consistent and troubling for at least 3 months
- Cognitive assessment score above 24 (adjusted for education level)
- Not pregnant, breastfeeding, or unwilling to use contraception if of childbearing age
- Not taken any experimental medications in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection that may help reduce Parkinson's symptoms when they fluctuate, such as when medication wears off. It is for people who are already taking levodopa but still have periods of poor symptom control.
This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.
This study tests a new form of Parkinson's medication given through a pump to see how well it works in everyday life for people in the early stages of advanced Parkinson's. It may help control symptoms and improve daily function.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
This study tests an experimental drug called LY3962681 in two groups: healthy volunteers and people with Parkinson's disease. The goal is to see if the drug is safe and how the body handles it, which may lead to future treatments for Parkinson's.
This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.